• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    The method of producing substituted amino acid derivatives of the general formula I (CHjU-NH-CH-Ra COOR, SU) is loalkyl with 3-6 UC L-Lode or alkoxycarbonyl, where Q is hydrogen. acetyl or benzyl-oxycarbonyl, or 2, or 1, their racemates or optical isomers or their pharmaceutically acceptable: l salts, o tl and h a and y and c, that a compound of general formula II00, CORf o -1 CHg ) n CO-SI- (CH;). h where A, n, q have the indicated meanings; - a lower alkyl radical or a # 1 -alkoxy radical whose amino-function is protected by such radicals as benzyloxycarbonyl or tert-butyloxycarboyl,
    公开号:SU1153827A3
    申请号:SU813344196
    申请日:1981-10-01
    公开日:1985-04-30
    发明作者:Винсен Мишель；Ремон Жорж；Лоби Мишель
    申请人:Адир (Фирма)；
    IPC主号:
    专利说明:

    - hydrokeyl or lower
    alkoxy radicals are peaKij iH reductive alkylation with a compound of the general formula III:
    R 0-C

    COOR,
    where R- and RJ have the indicated meanings with the release of the target product or with the removal, if necessary, of the N protected and ester groups by hydrogenolysis or saponification.
    Priority on the basis of signs: 02.10.80, with A is the benzene cycle, A is a saturated cycle, or T, R (is a lower alkyl group with
    J-4 carbon atoms containing an amino group; 5 R- is hydrogen or an alkyl group with 1-4 carbon atoms.
    R, is linear or branched
    an alkyl group having from 1 to 8 carbon atoms of the mon carbon of a mono- or dicycloalkyl-alkyl group or a phenyl alkyl group, sod; starch of up to 9 carbon atoms in total, or a substituted alkyl group of the formula
    - (CH2) p-y- (CH) (R4) -R5,
    Where. R, is cycloalkyl with 3-6 carbon atoms, Rg-CH, cycloalkyl with three six carbon atoms,
     where Q is hydrogen, p or 2,
     or 1;
    07.04.81. At R - hydrogen or lower alkyl with 1-4 carbon atoms, RJ - hydrogen, lower alkyl (except CH), benzyloxycarbonyl, Q acetyl or benzyloxycarbonyl.
    This invention relates to a process for the preparation of substituted amino acid derivatives of the general formula CO-CH-CCHjk-WI-CH-Ks where A is the benzene cycle, A represents the valuable cycle, or 1 R is a lower alkyl group with 1-4 carbon atoms containing an amino group RJ is a hydrogen atom or an alkyl group with 1-4 carbon atoms Da; R, is a linear or branched alkyl group with 1-8 carbon atoms, a mono- or dicycloalkyl-alkyl group or a phenyl-alkyl group containing up to 9 carbon atoms in total or an alkyl group of the formula - (CHpp-y-CH (R -R5 where R4 is hydrogen, lower alkyl with 1-4 carbon atoms or cycloalkyl with 3-6 carbon atoms; R ,, is hydrogen, lower alkyl with 1-4 carbon atoms, cycloalkyl with 3-6 carbon atoms or alkoxycarbonyl ,. or 7H-p, where 0 is hydrogen, acetyl or benzyloxycarbonyl, or 2, or 1, their racemates or optical isomers or their pharmaceutically Acceptable salts with inhibitory activity. The known reaction of adding nitrogen-containing compounds to carbonyl compounds. The conditions of the reaction depend on the structure of the starting compounds ftj. The purpose of the invention is to synthesize new compounds that have valuable pharmacological properties. I, which consists in that the compound of the general formula II is CHz co-CH-m U-NHj where A, n, q have the indicated values of the lower apical radical. or an aminoalkyl radical, the amino function of which is protected by such radicals as benzyloxycarbonyl or tert-butyloxycarbonide, the hydroxide or lower apkoxy radical, is subjected to a reductive alkylation reaction with a compound of the general formula III COOR RJ having the indicated values with the release of the target product or removing if necessary protective and ethereal groups of hydroge nol isome or deprivation. P pt and meper 1. 2-N-Cl-Kap6oKCH ethyl) - (5) alanyl1-3 5) -carboxI-1,2, 3,4-tetrahydroisoquinoline. Step AI (Levogyrate) tetrarirodroisoquinoline-3-carboxylic acid. In a three-necked flask with a reverse holsdilom, 15 g of (S) I -phenylalanine is introduced, then 34 ml of 40% growth. formalin thief and 105 ml of concentrated hydrochloric acid i Heat for 30 minutes in a boiling water bath. In this way, a clear solution is obtained, left to adjust to room temperature at the reaction mixture, and then 15 ml of formaldehyde and 30 ml of concentrated hydrochloric acid are added. It is then heated for 3 hours at reflux temperature pacTBopvire l. Allow to cool, then filter the precipitate 9T. After suction, it is treated with 200 ml of boiling water and 40 ml of hot ethanol. The solutions are combined and then neutralized by the addition of 10% ashyak. Tetrahydroquinoline-3-carboxylic acid crystallizes. The crystalline mixture is left for a night in the refrigerator, then the precipitate is separated 1174, sucked off and washed with ethanol. Thus obtain 17.3 g of the crude product. The product is dried over phosphoric anhydride under vacuum. G ,, H ,, N02-177 C 67.78; H 6.26; Calculated N 7.90. Found,%: C, 66.87; H 6.20-, N 7.96. IR spectrum: NH band at 28002400, C00 carbonyl band at 1630. Rotational capacity: oijj (, 2, 1 N NaOH). Stage B. Methyl-1,2,3, 5-tetrahydro-isoquinoline- (8) -3-carboxylate hydrochloride. In a three-neck flask, 5 g of tetrahydroisoquinoline-3-carboxylic acid and 30 ml of methanol are successively charged. This suspension is added by adding, to avoid exceeding the temperature of 0-5 ° C, 6 g of thionyl chloride. Addition takes about 10 minutes. At the end of the addition, stirring is maintained for 2 hours at room temperature, then the solvent is boiled at reflux temperature for 1.5 hours. After the mixture is completely dissolved, heating is stopped, then evaporated to dryness. The residue is treated with methanol by extraction three liters and then brought to dryness. 8 g of colorless crystals are obtained which are purified by trituration with ether. The filter Lip is filtered, sucked off, washed with ether and dried. 6.4 g of methyl tetrahydro-isoxoxinol-3-carboxylate are thus obtained. . C c, N „Ы 02НС1 227,69. Calculated,%: 58.03; H 6.20; N 6.15; C1 15.57. Found,%: C 57.79, H 6.46; N 6.38; C1 15.67. IR spectrum: carbonyl band at 1734, NHj band at 28002400 cm. Step B. Tert-butoxycarbonyl-2- (s) -alanyl-3 (S) -methoxycarbonyl-1,2,3,4-heterrahydro-isoquinoline. 6.01 g (0.0264 mol) of the hydrochloride obtained in the previous step is dissolved in 50 MP of water and the solution is alkalinized to pH 11 with
    NH OH, then extracted 2 times with 50 ml of sulfuric ether. The combined ether solutions are dried over calcium sulphate, filtered and the evaporated docs. The residual amino ester compound (5.04 g) is dissolved in 30 kp of dimethylformamide and this solution is added to a stirred solution of 5 g (0.0264 mol) tert-butylcarbonyl- (8) -alanine in 30 mp dimethyl forms and cooled to 0-5 C. To the resulting solution, 3.6 g (0.0264 mol) of 1-hydroxy-benzotriazole dissolved in 40 ml of dimethylformamide, then 5.45 g (0.0264 mol) of dicyclohexylcarbodiimide, dissolved in 30% chloroform, are added successively.
    The reaction mass is stirred for 18 hours as the temperature rises to room temperature. The dicyclohexyl urea formed is filtered off and the filtrate is evaporated to dryness under a vacuum of 0.1 mm Hg to obtain a residue, which is again dissolved in 50 ml of ethyl acetate and filtered again to separate the second portion of dicyclohexyl urea. The filtrate is washed successively with 80 ml of an aqueous saturated solution of NaCl, 2x40 ml of an aqueous solution of citric acid, again 80 ml of an aqueous saturated NaCl solution, 2x40 ml of an aqueous saturated NaHCO solution, and an aqueous saturated NaCl solution until neutral.
    The organic phase is dried over CaSO4, filtered and evaporated to dryness under vacuum. The residue after evaporation is the desired product. Weight. 9.1 g (96%); m.p. 98-100 ° C (according to Kofler).
    CigHzeN Of.
    Calculated,%: C, 62.97; H 7.23;
    N 7.73,
    Found,%: C, 63.15; H, 7.05; N7.97.
    Go Go.
    Tert.-butoxycarbonyl-2- (5) -alanyl-3- (5) -carboxy-1, 2,3,4-tetra hydro-isoquinoline.
    1.45 g (0.004 mol) of the compound obtained in the previous step are dissolved in 20 ml of methanol and 4.4 ml (0.004 mol) of 1N aqueous sodium hydroxide solution is added to the solution obtained. The solution is left for 20 hours at room temperature.
    The methanol is evaporated under a vacuum of a water jet pump and the residue is taken up in 20 ml of water. After extraction of the crude portion with ethyl acetate, the aqueous phase is acidified with 4.4 ml of 1N HCl. The resulting precipitate is extracted 2 times with 20 ml of ethyl acetate each time, the resulting solution is dried over CaSO4, filtered and evaporated. The resulting residue is the desired product, weight 1.3 g (93%).
    С (8 and гО Calculated,%: С 62.05; H 6.94, N 8.04.
    Found,%: C 61.64; H 6.98; N 7.78.
    Stage D.
    2- (8) -alanyl-3- (3) carboxy-1,2,3, 4-tetrahydro-isoquinoline.
    1.1 g (0.00316 mol) of the derivative obtained in the previous step are stirred at 5 ° C with 4.5 ml of anhydrous trifluoroacetic acid. The resulting solution is concentrated to dryness under a vacuum of 0.1. mmHg. The crystalline hygroscopic residue after evaporation represents the desired product in the form of trifluoroacetate, solvated with 0.5 mol of trifluoroacetic acid, wt. 1.3 g (98%).
    S., i.
    Calculated,%: C 45.83, H 4.21; N 6.68.
    Found,%: C 45.99; H 4.62; N.6,55.
    0.7 g (0.0019 mol) of the previous trifluoroacetate is converted to 0.45 g (94%) of the corresponding free amino acid by passing through a 50 g sulphonated resin (Dowex SOW) 8H), then eluting with 500 ml of 1N. ammonia solution. So pl, with decomposition. .
    Step E. 2- (N) 1-Carboxyl-ethyl- (S) -alanyl} -3-carboxy-1,2,3,4-tetrahydroisokinolin.
    0.849 g (0.0034 mol) of 2- (5) -al-g nsh1-3-carbrxi-1,2,3,4-tetrahydroisoquinoline is dissolved in the presence of 1.9 g (0.0216 mol) of pyruvic acid at 25 C in 22 ml of 1N sodium hydroxide and 50 ml of a buffer solution with pH 7j taken from a solution prepared from 50 MP of a 0.1 M solution of primary sodium phosphate and 29.1 ml of 0.1N. caustic soda solution. 0.45 g (0.0072 mol) of sodium cyanoborohydride is added immediately. The reaction mixture is incubated for 22 hours at a lump, at a natural temperature. The excess sodium cyanoborg peroxide is decomposed by the addition of 6 ivtn of concentrated hydrochloric acid. The resulting solution is passed through an ion exchange resin (Dowex 50 N). After elution with resin with distilled water until the chlorine ion is absent, the product fixed on the resin is eluted with 1 l of 1N aqueous ammonia solution. The ammonia solution is concentrated under vacuum of a water jet pump to dryness. The residue after evaporation is the mono ammonium salt of the desired product. The resulting weight is 0.8 g (69.7%). , Calculated,%: C 56.96; H 6.64; N 12.96. Found,%: C 57.79, H 6.69; N 12.70. And pmmere 2. 2- {3- (1-Carboxy-ethylamino) -2- (RS) methyl propanoyl j-3- (S) -carboxy-1,2,3,4-tetrahydroisoquinoline. Prepared according to example 1 (step B) from 3-tert.-butoxycar6onylamino-2- (K8) methyl propanoic acid and 3- (8) methoxycarbonyl-1,2,3,4-tetra-ro-isoquinoline. The obtained 2- 3-tert. -Butyroxicon-nano-amino-2- (RS) -methylpropane-3- (S) methoxycarbonyl-1,2,3, A-tetrahydro-isoquinoline is washed with an aqueous solution of caustic soda, using the method of example 1 (stage G). The resulting 2-3 tertiary. -butoxy1c bonylamino-2- (RS) methylpropanoyl-3- (8) carboxy-1,2,3,4-tetrahydro-iso-quinoline is treated with trifluoroxy acid with the method of example 1 (step D) to give 2- 3-amino trifluoroacetate 2- (K8) möts1 Propanoyl-3- (5) carboxy-1,2,3,4-tetrahydro-iso-quinoline, which is converted to chlorine hydrate by dissolving in excess of 1N. HC1 and concentrating to dryness. C, 4H, VClNtOj. Calculated,%: C, 56.28; H 6.41; N 9.38; C1 11.87. Found,%: e, 56.4 H; 6.59; N 9j04; C1 11.94; C 56.94; H 6.62, N 8.97} C1 11j87. . 1.3 g (0.005 mol) of methyl-3-amino-propanoyl-3- (S) carboxy-1,2, 3,4-tetrahydroisoquinoline obtained in the preceding stage (K5) is dissolved in 20 ml of methanol containing 0.009 mol of HC 1 and 0.515 g of 94% pyruvic acid (0.0055 mol). The solution is hydrogenated under a pressure of 0.5 bar in the presence of 1 g of 10% palladium-on-carbon. About half of the theoretical amount of hydrogen is adsorbed for 1 hour. The suspension is filtered, 0.515 g of pyruvic acid is added to the filtrate, then neutralized to pH 7-7.2 with triethylamine. After adding 1 g of 10% palladium-on-carbon, the suspension is hydrogenated again under a pressure of 0.5 bar until the starting primary amine disappears, which is monitored by thin layer chromatography to detect this amine using nin hydride. The reaction mixture is filtered and the condensation filtrate is dissolved in 25 MP of water and passed through 125 ml of ion exchange resin (Dowex 50 N). A product fixed on the resin was eluted with 500 ml of aqueous 1N ammonia solution, and then 260 MP of distilled water. The combined eluates are evaporated to dryness. The residue after evaporation is the desired product as a mono ammonium salt. The resulting weight is 0.6 g., 05. Calculated,%: C 58.11, -H 7.17; N 11.43. Found,%: C 58.91; H 6.93; N 11.96 .. Example 3. 1- (N-tl- (RS) -Karboxy-ethyl- - (S) alanyl -2-carboxyperhydroindole. Stage A. 2- (K8) carboxy-ivdoline. 31.5 g of this indoline (86%) is obtained by saponification in 250 ml of 1N sodium hydroxide solution and 150 ml of ethanol for 18 hours at room temperature, 43 g (0.224 mol) corresponding to ethyl ether.The aqueous-alcoholic solution is concentrated by half, neutralized with 25 ml of 10 n hydrochloric acid, the precipitate formed is filtered off, washed with water and dried.The crude acid is purified by passing through a column of ion exchange resin (Dowex H) and eluting with 2N water. ammonium salt. The obtained ammonium salt is dissolved in mini-magyma / water and the acid is precipitated with a theoretical calculated amount of HC 1. Sucked off, washed with water and dried in air. SpN, 2 NjO (ammonium salt). Calculated,% 59.99; H 6.71; N 15.54. Found,%: C 60.22; H 6.71; N 15.06; C 59.93; H 6.71; N 15.29. Stage B. 2- (S) -Carboxy-indoline, 60.5 g (0.37 mol) of 2- (DL) -Kap6oKsi-nndolin obtained in step A, is added to a solution of 44.9 g (0.37 mol) ( +) - C-methylbenzylamine in 400 ml of anhydrous ethanol. The precipitate obtained is filtered off with suction and extracted (extracted) into 350 ml of anhydrous isopropanol at reflux temperature. After cooling, the suspension is filtered, the precipitate is washed with a small amount of isopropanol and dried. The resulting weight is 2- (b) -carboxy-indoline, salt () -o-methylbenzylamine 29.8 g, 3 (c 1; ethanol). 2- (S) -Carboxy-indoline is obtained in theoretical yield by dissolving 10 g of the previous salt (0.029 mol) in 50 mp of water and acidifying 29 ml of 1 n hydrochloric acid. The precipitate is drawn off, washed with water, distilled and dried. Optical purity: 96% (C.P.V. after isolation in the form of an amide of (-) - campanic acid). 2- (K) -Carboxy-nndolin is obtained in the same way from (E8) -carboxy-indoline and (-) - ob-methylbenznlamine. The absolute configurations of kislot (s) and (r) are defined as follows. Analytical amounts (about 0.5 g) of each of the acids are converted to ethyl esters by treatment with thionyl chloride and ethanol according to the method of step B. The esters reduce the aluminum aluminum hydride according to EJCOR EY (cited above) to the corresponding primary alcohols, which are identified by their rotational ability in comparison with alcohols, the corresponding absolute configurations of which are known. Stage B. 2- (8) Ethoxycarbonyl-perhydroid. 11 g of 2- (b) -carboxy-indoline in the form of the salt (+) - x-methylbenzylamine (0.032 mol) obtained in stage B is dissolved in 100 ml of water and converted into the corresponding acid by the addition of 32 ml of 1N. HC1. The acid is sucked off, washed with water and dried in a desiccator over phosphoric anhydride, then suspended in 50 ml of anhydrous ethanol. At 0-5 ° C, 3.9 ml of thionyl chloride is added over 10 minutes with stirring, stirring is continued for 1 hour at 25 ° C, then 1 hour at. The mixture is left overnight at 25 ° C, then concentrated to dryness under vacuum pump at 40 ° C and treated with 50 ml of anhydrous benzene and sucked off. The resulting hydrochloride 2- (8) etok-. Sicarbonyl-indoline is hydrogenated in a solution in 150 ml of water in the presence of 2 g of palladium-containing coal for 8 hours at 45 ° C under a pressure of 50 kg / cm. After cooling and filtering off the catalyst, the filtrate is evaporated to dryness. The residue is the desired product as the hydrochloride. Weight 6.9 g (93%). C, 8 2oClN02. Calculated,%: C 56.52; H 8.62; N 5.99; C1 15.17. Found,%: C 55.52, H 8.53, N 5.96; S1.15,16. Stage G. N- | XS) -t-Boc-alanil -2- (S) ethoxycarbonyl-perhydroindole. A solution comprising 3g (0.0128 mol) of 2- (S) -ethoxycarbonyl-per-hydroindole hydrochloride obtained in the preceding step (1), 15 ml of anhydrous dimethylformamide (DMF) and 1.8 ml of triethylamine are added to the mixture cooled to 5c. and to a stirred solution of 2.42 g (0.0128 mol) of t-Boc (L) alanine in 15 ml of DMF. To the resulting mixture is added sequentially a solution of t, 7 g (0.0128 mol) of N-hydroxybenzotriazole in 20 ml DMF, then a solution of 2.64 g (0.0128 mol) of dicyclohexylcarbodiimide in 15 ml of anhydrous chloroform. After stirring for 65 hours at 25 ° C, the dicyclohexylurea formed is filtered off and washed with ethyl acetate. The combined filtrates are washed successively with 80 ml of a saturated aqueous NaCl solution,
    2 times 40 MIT. Of a concentrated solution of citric acid, 2 times in 40 ml of an aqueous saturated solution of NaHCOj, then again 2 times in 40 ml of a solution of NaCl.
    The organic solution is dried over CaS04, filtered, and concentrated to dryness under vacuum of a water-jet pump. The residue is treated with 100 ml of ethyl acetate. The solution is filtered to remove the last traces of dicyclohexyl urea, concentrated to dryness of the filter gives a residue, which is the desired product in the form of a very viscous oil.
    Bes 3.8 g (91%).
    CigHj N.Oj.
    Calculated,%: C, 61.93; H 8.75; N 7.60.
    Found,%: C 61.76; H 8.56; N 7.77.
    Stage D.
    N- (S) -t-Boc-alanil -2- (S) carboxy-perhydroindole.
    3.6 g (0.0098 mol) of the ester obtained in Step D are dissolved in 30 ml of methanol in the presence of 11 ml of an aqueous 1N sodium hydroxide solution.
    After 20 hours at 25 ° C, the methanol is evaporated under a vacuum of a water jet pump and 60 mp of water is added. The solution is washed with 2 times 30 ml of ethyl acetate to remove the unrefined portion, then acidified with 11 ml of 1N. hydrochloric acid. The white precipitate formed is distilled twice with 50 ml of ethyl acetate, the extracts are combined and washed with water, dried over CaSO4, filtered and concentrated to dryness. The remainder is the desired product. Weight 1.9 g (57%).
    C..Og.
    Calculated,%: C 59.98; H 8.29;
     . N 8.23.
    Find about%: C 59,10; H 8.16; N 7.81.
    Stage E.
    1- (S) -Alanyl-2- (5) carboxy-pergyroindole.
    1.6 g (0.0047 mol) of the acid obtained in the preceding stage D are stirred at 0–5 ° C in 10 ml of trifluoroq, hydrochloric acid for 1 h, then for 15 min at room temperature.
    After evaporation to dryness under vacuum of a vane pump, the residue
    dissolved in 15 mp of water and passed through a column with ion exchange resin (Dowex +8 N). The column was eluted with 1 l of aqueous 2N ammonium solution. The eluates are concentrated to dryness under vacuum. The resulting residue is the desired product. Weight 0.90 g (95%).
    CjH-i NjO ,.
    Calculated,%: C 59.98; H-8.39, N11.10.
    Found,%: C 58.53; H 8.24; N 11.43.
    Stage G.
    l-fM 1- (CZ) -carboxy-ethyl - (5) alanyl -2- (8) carboxyper1hchroindol.
    0.7 I (0.00291 mol) L- (8) Alash-2- (3) carboxy-perhydroindole, obtained in the previous step (E), and 1.67 g (0.0183 mol) of pyruvic acid are dissolved in 18 ml. 1 n. an aqueous solution of sodium hydroxide and 40 MP buffer solution with a pH of 7, the resulting solution is subjected to recovery using 0.400 g (0.0064 mol) of sodium cyanoborg.hydride as described in Example 1, step E.
    After treatment with concentrated hydrochloric acid and passing through an ion exchange resin (Dowex 50 P), the evaporated ammonium eluate that is evaporated to dryness gives 0.76 g (79%) of the residue, which represents the co6ofi product in the form of a mono ammonium salt.
    C ,, Hj / N, 05.
    Calculated,%: C 54.70; H 8.26; N 12.76.
    Found,%: C 54.10 H 7.78; N 12.77.
    Example 4. N - ((RS) 3TOK hydroxycarbonyl ethylthio -1- (RS) ethoxycarbonylethyl -1- (S) alanyl -2- (S) carboxy-pero hydroindole.
    1 g (4.17 mmol) of 1- (8) alanyl-2 - (8) carboxy-perhydro-ddol prepared in Example 3, Step E, and 4.72 (19 mmol) of ethyl-G1- (RS) ethoxycarbonyl-ethylthio - Pyrivate was dissolved in 50 m of anhydrous ethanol in the presence of 15 4 A. molecular sieve. After stirring for 45 minutes at room temperature, 0.25 g of sodium cyanoborohydride was added in 6 hours as a solution in 2.25 mp of anhydrous ethanol. After separating the molecular sieve by filtration, the filtrate is concentrated to dryness under reduced pressure, and the residue is dissolved 131 in 100 MP ether. The solution is extracted 2 times with 100 ml of distilled water, then dried over sulfide, filtered and chromatographed on 200 g of silica (Merck F 254), eluting with a mixture of chlorine methylene and methanol 180/20. 0.5 g (25%) of the desired product is obtained in the form of sodium salt. Cj2 Hj N OjiSNa. Calculated,%: C, 53.43; H 7.13; N 5.66; S 6.48. Found,%: C, 53.28; H, 7.09; N, 5.19; S 5.92. Intermediate ethyl- 1- (K5 ethoxycarbonyl-ethylthio-pyruvate is obtained by condensation of ethyl bromopyruvate with ethyl- (K8) thiolactate in the presence of pyridine according to the method for close derivatives. 67% boil output. 165 mm Hg. Example 5. (Ethoxycarbo nylmethylthio) -1- (RS) ethoxycarbonyl-ethyl -1- (3) alen-1-2- (8) carboxy-pe hydroindol. Prepared according to example 4 from 1 g (4.17 mmol) 1- (5) -alanip -2- (5) -carboxy-perhydroindole, 4.45 g (t, 9 mol of methyl- (carbethoxymethylthio) pyruvate and 0.25 g of sodium cyanoborohydride. After purification by chromatography, 0.26 g (14%) of the desired product is obtained .Cj, .as %, C 55.0; H, 7.47; N, 6.11; S, 6.99; Found,%: C, 54.71; H, 7.32; N, 5.94; S, 7.01. - (carboethoxime tilmercapto) -1daruwat is obtained by condensation of etidibromine with methyl thioglycollate. Yield 50%. T.KIP. 165-175c / 15 mHg. And p and mr.p 6. (L-benzyloxycarbonyl) -N ( Dicyclopropylmethyl amino) -1- (RS) ethoxycarbonyl-propych - (5) Alansh -1 -2- (8) -carboxy-perhydro indole. Prepared according to Example 4 from 0.6 g 1- (S) alanyl-2- (5 ) -carboxy-perhydroindole, 4.3 g ethyl-t4- (K) benzyloxycarbonyl-dicyclopropamide -2-oxo, -butyrate, and 0.15 g daanrborohydride sodium. After purification by chromatography, 1 g (67%) of the desired product, C, 07, is obtained. 7 Calculated,%: C, 66.31; H 7.93, N 7.03. Found,%: C 66.11; H 7.83, N 7.22. The intermediate methyl-t4- (N) -benzyloxycarbonyl 3-dicyclopropyl-amino (-2-oxo) butyrate is obtained in 6 steps as follows. Step 1. Condensation of diethyl acetal bromo ketaldehyde with ethyl 2-dithianyl carboxylate. Care 57%, bk. 130-135 ° C / 0.07 mm Hg Stage 2. The resulting 2- (2,2-diethoxy-1-etsh1) -2-carbethoxydithian-1, 3 is converted to 2- (2-oxo-1-ethyl) -2-carbethoxy-dithian-1, 3 semicarbazone by stirring with a solution of semicarbazide hydrochloride in water at room temperature for 24 hours. Semicarbazone is decomposed with a yield of 88%. (by Kofler). Step 3. Semicarbazone is converted to the corresponding aldehyde by mixing with pyruvic acid and water-acetone solution. Yield 50%, bk. 140-145 C / 0.8 mm Hg Stage 4. The precursor aldehyde is condensed with dicyclopropylamine and the resulting amine is reduced according to a known method, thus obtaining 2- (2) -dicyclopropane methylamine- (ethyl) -2-carbethoxy-dithian-1,3 in 65% yield. His hydrochloride melts at 150 K. Step 5. The derivative obtained in the preceding stage is subjected to the action of benzyl chloroformate according to a known method. 2-C2- (H-) Benzyloxycarbonyl} dicyclopropylmethylamino- (1-ethyl) 2-carbethoxy-dithian-1, 3 is a viscous oil obtained with the release of Step 6. Under the action of N-bromo-succinium in a water-acetone solution the derivative obtained at the preceding stage is converted into ethyl-G4- (N) -benzyloxycarbonate (dicyclo-popylamino) -2-ocean3 butyrate with a yield of 70% according to a known method. The compounds obtained in the pre- and their examples, like other compounds of formula (D), obtained in a similar manner, are presented in Table 1. For arbitrariness, the symbols A and p are indicated only for the values A and the benzene cycle and n t. l of all other compounds And means a complete cycle and (perhydroindole).
    fi115
    Table 2 shows the characteristic values of the compounds in the IR and NMR spectra.
    A pharmacological study of the compounds is carried out by administering an intravenous or orally live dog.
    The dogs' blood pressure is measured with a pressure gauge (Statham P 23 Db) after aortic catheterization with the femoral artery. Registration is performed using a recording apparatus (Brush 400).
    Angiotensin I and Angiotensin II are administered by intravenous injection to animals at a dose of 0.3 tj / kg. The compounds are then administered orally or intravenously at a dose of 1-5 mg / kg.
    The inhibition of the hypertensive activity of angiotensin I, reaching up to 50-100% 30–90 minutes after the administration and maintained at 40–80% later than 6 hours after the administration, is noted. Some compounds remain active after 24 hours, in contrast to the well-known captopril in particular. In addition, the compounds do not exhibit any toxicity (DLp 500 mg / kg intraperitoneally in myr). 1 (Example l) O CH, (A benzene,) 2 (Example 2) (A benzene,) 1 CH 3 (Example 3) OCH, 1 OCH, 2 "5-CH OCH, CjHy-CH OCH, -CH OSSH
    7
    Sratsitelny data on pktinosti proposed compounds and compounds captopril, which has the formula
    .soon
    COCHCH SH CHZ
    summarized in table 3. Results were obtained after administration of the test substances through the mouth (CR) and intravenous (IV). The decrease in blood pressure was monitored by the intensity of angiotexin inhibition 1 and 6 hours after administration.
    Content, mg: 1- {H- 2-1- (8) Ethoxycarbonyl-ethylthio-1- (K8) ethoxycarbonylethyl - (S) alanyl -2- (S) carboxy-perhydroindole-maleate 10, wheat starch 120, corn starch 115, formalin-treated casein 20, magnesium stearate 15, talc per tablet 20.
    Thus, new compounds with valuable pharmacological and n properties have been obtained.
    Table 7 Ammonium salt Am1-Yun salt Ammonium salt Kisly mape eIg-: n1 (-): M), Ng-CH Sour maleate
    1,3)
    Arrays: OH (4.63, 7) 24 (2.5-3)
    19H (2.5-1)
    Arrays: 17H (1.6-2H (5.7-5.2
    Arrays: 21H (2.7-1) S: 2H (6.4)
    Arrays: 20H (2.7-1.1) S: 2H (6.4)
    Arrays: 8H (4.7-3.2) d: 2H (2.9) 1730 16501600
    Arrays: 39H (4,617301690
    CO amide
    16501660 W 3300 CO ester Arrays: 11H (4.5CO amide
    Tablnca2 0.8)
    6H (4.5-3.5) 10H (0.7-0.1) ZN (3.2-1.9) 6H (4.6-3.7) 11H (0.8-0.1) 4H (11.2) 4H (10.3) 6H (4.7-3.9) 39H (2.5-1)
    S: 2H (5.1) 0.15) 5H (7.3) 23H (2.52, 6) S: 2H (6.5) 4H exchangeable 1) (11.1)
    . Arrays: 9H (4.7-3.2
    eleven
    2
    NH 3600-2300
    CO complex
    Arrays: 6H (3-4,5) d: 6H (1)
    ether 1725
    CO amide 1630
    NH h-36 00-2 300
    3 CO complex
    Arrays: 6H (4.5-3.3) q: 2H
    1730 broadcast
    1650SO E1ZhD 1550
    NH 3700-2500
     complex
    Arrays: 18H (2-1) q: 4H (4.25)
    ether 1720
    1625
     amide
    NH 3500-3000 1680 Arrays: 19H (2,) 1550 NH 3600-3100 ester 1725 Arrays: 6H (3-4.5) amide 1620 t. 3300 ester 1725 Arrays: 24H (2.4-0.7) amyd. 1620 NH 3300 ester Arrays: 25H (2.5-0) ester 1725 amide 1610 NH 3300 ester 1725 Arrays: 5H (4.5-3) amv NH 3600-2500 ester {730 Arrays: 6H (3, -4 , 6 amide 1610
    . Continuation of the table.2 25N (2.5-1) 20N (1.2-2.5)
    4H exchanged35H (0.3-2.5) ems (8.7-7.7)
    S: 2H (3.4) 2H (2.5-2) 4H (4.5-3.2) d: 2H (3)
    2H exchanged
    7H (4.5-2.5) S: 3H (t, 9) 8H (0.9-0.1) NMR in 6H (4.6-3.4) 6H (4.5-3) 1Ж2, 9) 23H (0.6-2.3) 0.1-2.5) (6.8) 0.7-2.5) 23. 1153827. 21Ш 3300 ester 1735 Arrays: amide 16501600 22NH ZZOR S-0 complex. ether 1725 Arrays: amide 1610 23. Shg + ZBOOS O ester 1730 Arrays: amide 1650 1550 24NH 3700 ester. 1730 Arrays: amide 1600 | 25 NH2 + 35002300 ester 1740 Arrays: amide 1650 26: NHz + 33403200 3400 CO e ester 1720 Arrays: CO amide 1650 27NNg + ЗЗОО2300 acid 1780 Arrays:. .1740 amide 1640 amide ester 24: Continuation of Table 2: 11H (/ 4.6-2.9) S: 3H (2.1) 26H (2.4-1) 7H (3-5) 28H (0.5 -2,6). 6H (3-4,7) 2H exchangeable (5.9) ZON (0.8-2.6) 32H (2.6-0) 10H (5-2.8) .. 6H (3.5-4 , 6) ZN exchangeable (8-9) 34H (0.6-2.7) 27H (2.2-2H exchangeable C5.8) 0.7) 7H (4.8-3),. 29H (2.5 - -. 0.7) 4H (4.5-3.5) 4H (2.5-3.5) HMR c.
    25
    26
    1153827
    Table3
    权利要求:
    Claims (1)
    [1]
    The method of obtaining substituted amino acids of the General formula I
    NH-CH-R3 coor 2 where 'A A R <cycle, n = 1; n-0 cycle or
    I 2
    J;
    e sobenzene saturated lower alkyl group of 1-4 carbon atoms holding an amino group;
    a hydrogen atom or an alkyl group with 1-4 carbon atoms;
    - a linear or branched alkyl group with 1-8 carbon atoms, a mono- or di- ~ cycloalkyl-alkyl group, or a phenyl-alkyl group containing a total of up to 9 carbon atoms or a substituted alkyl group of the formula
    - (CHPjT y - (cn) (r 4 ) -r 5 Where R ^ is hydrogen, lower alkyl with ι 1-4 carbon atoms or cycloalkyl with 3-6 carbon atoms;
    Rg “hydrogen, lower alkyl with 1-4 carbon atoms, picloalkyl with 3-6 carbon atoms or alkoxycarbonyl, y = S or> S-0, where Q is hydrogen acetyl or benzyl-hydroxycarbonyl, p = 1 or 2, q = 0 or 1, their racemates or optical isomers or their pharmaceutically acceptable salts, which, characterized in that, the compound of General formula II.
    COR7
    And where
    CH z ) n 'CO —CH— (cn g £ - nn g Rt 6
    A, n, q have the indicated meanings; R + e is a lower alkyl radical or aminoalkyl radical, the amino function of which is protected by radicals such as benzyloxycarbonyl or tert-butyloxycarbonyl,
    1 153827
    R * - hydroxyl or lower alkoxyl radicals, are subjected to a reductive alkylation reaction with a compound of the general formula III:
    R ο = οζ COOR 2 where Rj and Rj have the indicated meanings, with the isolation of the target product or with the removal of N protecting and ether groups, if necessary, by hydrogenolysis or saponification.
    Priority by signs:
    02.10.80 ”at A - benzene cycle, n = 1, A - saturated cycle, n = 0 or 1,
    R f is a lower alkyl group c. . 1-4 carbon atoms containing an amino group;
    R 2 is hydrogen or an alkyl group with 1-4 carbon atoms,
    R 3 ~ linear or branched alkyl group with 1-8 atom +. mi carbon mono - or dicycloalkyl-alkyl group or phenyl-alkyl group containing a total of up to 9 carbon atoms or a substituted alkyl group of the formula
    - (CH 2 ) p -y- (CH) (R 4 ) -R 5 , where R4 is cycloalkyl with 3-6 carbon atoms, R 5 -CH3, cycloalkyl with three to six carbon atoms, y = S ππη> Ν-0, where Q is hydrogen, p = 1 or 2, q = 0 or 1;
    04.07.81. When R ^ is hydrogen or lower alkyl with 1-4 carbon atoms, Rg is hydrogen, lower alkyl (except for CH 3 ), benzyloxycarbonyl, Q = acetyl or benzyloxycarboyl.
    类似技术:
    公开号 | 公开日 | 专利标题
    SU1153827A3|1985-04-30|Method of obtaining substituted aminodiacids,their racemates or optical isomers,or their pharmaceutically acceptable salts
    US4508729A|1985-04-02|Substituted iminodiacids, their preparation and pharmaceutical compositions containing them
    EP0236872B1|1992-11-25|Hydroxyl amine derivatives, their preparation and use as medicaments
    EP0054862B1|1985-11-27|Substituted dipeptides, processes for their preparation and pharmaceutical compositions containing them and their use in the inhibition of enkephalinase
    US4128653A|1978-12-05|Reduction of blood pressure with carboxyalkylacyl-pipecolic acid derivatives
    US5591891A|1997-01-07|N-[Mercaptoacyl | ] compounds and S-lipophiIic aliphatic carbonyl derivatives thereof as antihypertensives
    KR910000234B1|1991-01-23|Process for preparing cis,endo-2-azabicyclo|decane-3-carboxylic acil derivatives
    CA1294736C|1992-01-21|Renin inhibitors containing 5-amino-2,5-disubstituted- 4-hydroxypentanoic acid residues
    FR2575753A1|1986-07-11|NOVEL PEPTIDE DERIVATIVES WITH A NITROGEN POLYCYCLIC STRUCTURE, PROCESS FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
    US4397857A|1983-08-09|Azabicyclooctane-carboxylic acids and pharmaceutical compositions containing them and antihypertensive use thereof
    FR2518088A1|1983-06-17|NOVEL AMINOACID DERIVATIVES AND THEIR THERAPEUTIC APPLICATION
    NZ244985A|1995-06-27|Peptide compounds, preparation and pharmaceutical compositions thereof
    GB2086393A|1982-05-12|Bicyclic compounds
    US4154937A|1979-05-15|Hydroxycarbamoylalkylacylpipecolic acid compounds
    CA2266514A1|1998-05-07|Novel | peptide derivatives, method for making same and therapeutic applications thereof
    DE2730549A1|1978-01-19|PEPTIDE DERIVATIVES AND THEIR PRODUCTION
    US4565819A|1986-01-21|Substituted imino diacids, their preparation and pharmaceutical compositions which contain them
    US5432159A|1995-07-11|N-|carbonyl dipeptide antihypertensive agents
    US4490386A|1984-12-25|Phosphate salts of 1-[2-[|-amino]-1-oxoalkyl]octahydro-1H-indole-2-carboxylic acids, preparation of, and medical compositions thereof
    US5380921A|1995-01-10|Aminophosponic acid derivative
    IE871872L|1988-01-14|Thiazolidine-4-carboxylic acid derivatives
    IE48497B1|1985-02-06|Derivatives of pyrrolidinecarboxaldehyde and piperidinecarboxaldehyde and intermediates therefor
    US4616030A|1986-10-07|Perhydroindole-2-carboxylic acids as antihypertensives
    US4616029A|1986-10-07|Perhydromdole-2-carboxylic acids as antihypertensives
    US4616031A|1986-10-07|Perhydroindole-2-carboxylic acids as antihypertensives
    同族专利:
    公开号 | 公开日
    NO813339L|1982-04-05|
    LU88262I2|1994-02-03|
    GR75016B|1984-07-12|
    JPH0132239B2|1989-06-29|
    KR860001875B1|1986-10-24|
    DD201783A5|1983-08-10|
    OA06914A|1983-05-31|
    HU185147B|1984-12-28|
    AT7910T|1984-06-15|
    AU542611B2|1985-02-28|
    AU7594981A|1982-04-08|
    NL930046I2|1994-01-03|
    AR242949A1|1993-06-30|
    FR2503155B2|1983-07-01|
    UA6308A1|1994-12-29|
    DK434381A|1982-04-03|
    PT73755B|1983-10-11|
    FI77230C|1989-02-10|
    IE51821B1|1987-04-01|
    NO160780B|1989-02-20|
    CA1341196C|2001-03-06|
    IL63940D0|1981-12-31|
    PH17516A|1984-09-13|
    FI813034L|1982-04-03|
    ES8305723A1|1983-04-16|
    IL63940A|1985-06-30|
    MD381C2|1996-05-31|
    PT73755A|1981-11-01|
    DE3164201D1|1984-07-19|
    EP0049658B1|1984-06-13|
    IE812257L|1983-03-29|
    FR2503155A2|1982-10-08|
    NO160780C|1989-05-31|
    DK157011C|1990-03-26|
    EP0049658A1|1982-04-14|
    KR830007564A|1983-10-21|
    DK157011B|1989-10-30|
    FI77230B|1988-10-31|
    NZ198535A|1984-09-28|
    ES505999A0|1983-04-16|
    NL930046I1|1993-09-01|
    EG15361A|1987-04-30|
    JPS5791974A|1982-06-08|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    JPS5751834B2|1978-11-27|1982-11-04|
    IL58849A|1978-12-11|1983-03-31|Merck & Co Inc|Carboxyalkyl dipeptides and derivatives thereof,their preparation and pharmaceutical compositions containing them|
    US4461896A|1979-02-07|1984-07-24|Norwich Eaton Pharmaceuticals, Inc.|1-[Acylthio) and -1-oxoalkyl]-1,2,3,4-tetrahydroquinoline-2-carboxylic acids|
    EP0018104B1|1979-03-26|1983-05-25|Takeda Chemical Industries, Ltd.|Tetrahydroisoquinolines, their production and the compounds and pharmaceutical compositions containing them for use in the prevention or treatment of hypertension|
    US4294832A|1979-04-28|1981-10-13|Tanabe Seiyaku Co., Ltd.|Tetrahydroisoquinoline compounds and a pharmaceutical composition thereof|
    GB2048863B|1979-05-16|1983-06-15|Morton Norwich Products Inc|Tetrahydroisoquinoline-3-carboxylic acids|
    US4303583A|1979-08-13|1981-12-01|American Home Products Corporation|1H,5H-[1,4]Thiazepino[4,3-a]indole-1,5-diones|
    FR2470767B1|1979-12-07|1982-04-30|Science Union & Cie|
    FR2487829B2|1979-12-07|1983-11-25|Science Union & Cie|
    ZA811493B|1980-04-02|1982-03-31|Warner Lambert Co|Substituted acyl derivatives of octahydro-1h-indole-2-carboxylic acids|
    US4251444A|1980-04-07|1981-02-17|American Home Products Corporation|Thiazepino-[4,3-b]-isoquinoline-1,5-dione derivatives and precursors|
    DE3177311D1|1980-08-30|1994-06-09|Hoechst Ag|Amino acid derivatives, processes for their preparation, compositions containing them and their use.|
    US4344949A|1980-10-03|1982-08-17|Warner-Lambert Company|Substituted acyl derivatives of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acids|DE3177311D1|1980-08-30|1994-06-09|Hoechst Ag|Amino acid derivatives, processes for their preparation, compositions containing them and their use.|
    US4344949A|1980-10-03|1982-08-17|Warner-Lambert Company|Substituted acyl derivatives of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acids|
    US4532342A|1981-02-20|1985-07-30|Warner-Lambert Company|N-substituted amino acids as intermediates in the preparation of acyl derivatives of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acids|
    DE3174844D1|1980-10-23|1986-07-24|Schering Corp|Carboxyalkyl dipeptides, processes for their production and pharmaceutical compositions containing them|
    ZA817261B|1980-10-23|1982-09-29|Schering Corp|Carboxyalkyl dipeptides,processes for their production and pharmaceutical compositions containing them|
    US4479963A|1981-02-17|1984-10-30|Ciba-Geigy Corporation|1-Carboxyalkanoylindoline-2-carboxylic acids|
    IN156096B|1981-03-19|1985-05-11|Usv Pharma Corp|
    EP0065301A1|1981-05-18|1982-11-24|Merck & Co. Inc.|Isoquinoline carboxylic acid derivates, process for preparing and pharmaceutical composition containing the same|
    SU1327787A3|1981-11-05|1987-07-30|Хехст Аг |Method of producing cis,endo-2-azabicyclo--octane-3-carboxylic acids or acid-additive salts thereof|
    DE3226768A1|1981-11-05|1983-05-26|Hoechst Ag, 6230 Frankfurt|DERIVATIVES OF CIS, ENDO-2-AZABICYCLO--OCTAN-3-CARBONIC ACID, METHOD FOR THE PRODUCTION THEREOF, THE MEANS CONTAINING THEM AND THE USE THEREOF|
    AT25244T|1981-12-29|1987-02-15|Hoechst Ag|NEW DERIVATIVES OF BICYCLIC AMINO ACIDS, METHOD FOR THE PRODUCTION THEREOF, THE MEANS CONTAINING THEM AND THE USE THEREOF AND NEW BICYCLIC AMINO ACIDS AS INTERMEDIATE STAGES AND METHOD FOR THE PRODUCTION THEREOF.|
    CA1341296C|1981-12-29|2001-09-25|Hansjorg Urbach|2-azabicycloalkane-3-carboxylic acid derivatives, processes for their preparation, agents containing these compounds and their use|
    DE3210496A1|1982-03-23|1983-10-06|Hoechst Ag|NEW DERIVATIVES OF BICYCLIC AMINO ACIDS, METHOD FOR THE PRODUCTION THEREOF, THE MEANS CONTAINING THEM AND THE USE THEREOF, AND NEW BICYCLIC AMINO ACIDS AS INTERMEDIATE STAGES AND METHOD FOR THE PRODUCTION THEREOF|
    DE3302125A1|1983-01-22|1984-07-26|Boehringer Ingelheim KG, 6507 Ingelheim|AMINO ACID DERIVATIVES, METHOD FOR THE PRODUCTION AND USE THEREOF|
    HU191120B|1983-01-31|1987-01-28|Hoechts Ag,De|Process for raceme separation of optically active byciclic imino-alpha-carbonic acid esthers|
    US5175306A|1983-01-31|1992-12-29|Hoechst Aktiengesellschaft|Process for the resolution of racemates of optically active bicyclic imino-α-carboxylic esters|
    DE3303344A1|1983-02-02|1984-08-02|Hoechst Ag, 6230 Frankfurt|METHOD FOR PRODUCING N-ALKYLATED AMINO ACIDS AND THEIR ESTERS|
    DE3333455A1|1983-09-16|1985-04-11|Hoechst Ag, 6230 Frankfurt|METHOD FOR PRODUCING N-ALKYLATED DIPEPTIDES AND THEIR ESTERS|
    DE3333454A1|1983-09-16|1985-04-11|Hoechst Ag, 6230 Frankfurt|METHOD FOR PRODUCING N-ALKYLATED DIPEPTIDES AND THEIR ESTERS|
    DE3408923A1|1984-03-12|1985-09-26|Hoechst Ag, 6230 Frankfurt|CARBOXYALKYLDIPEPTIDE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, THE AGENTS CONTAINING THEM AND THE USE THEREOF|
    DE3413710A1|1984-04-12|1985-10-24|Hoechst Ag, 6230 Frankfurt|METHOD FOR TREATING HEART INSUFFICIENCY|
    US5684016A|1984-04-12|1997-11-04|Hoechst Aktiengesellschaft|Method of treating cardiac insufficiency|
    DE3431541A1|1984-08-28|1986-03-06|Hoechst Ag, 6230 Frankfurt|CIS, ENDO-2-AZABICYCLOALKAN-3-CARBONIC ACID DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AND INTERMEDIATE PRODUCTS IN THEIR PRODUCTION|
    GB8422165D0|1984-09-01|1984-10-03|Wellcome Found|Compounds|
    US5231080A|1985-10-15|1993-07-27|Hoechst Aktiengesellschaft|Method for the treatment of atherosclerosis, thrombosis, and peripheral vessel disease|
    US4693996A|1985-12-23|1987-09-15|Warner-Lambert Company|Method of treating heart failure and medicaments therefor|
    US5231084A|1986-03-27|1993-07-27|Hoechst Aktiengesellschaft|Compounds having a cognition adjuvant action, agents containing them, and the use thereof for the treatment and prophylaxis of cognitive dysfuncitons|
    DE3633496A1|1986-10-02|1988-04-14|Hoechst Ag|COMBINATION OF ANGIOTENSIN CONVERTING ENZYME INHIBITORS WITH CALCIUMANTAGONISTS AND THEIR USE IN MEDICINAL PRODUCTS|
    DE3639879A1|1986-11-21|1988-06-01|Hoechst Ag|METHOD FOR PRODUCING MONO, BI AND TRICYCLIC AMINO ACIDS, INTERMEDIATE PRODUCTS OF THIS METHOD, AND A METHOD FOR PRODUCING THE SAME|
    DE3722007A1|1987-07-03|1989-01-12|Hoechst Ag|METHOD FOR PRODUCING BICYCLIC AMINOCARBONIC ACIDS, INTERMEDIATE PRODUCTS OF THIS METHOD AND THE USE THEREOF|
    FR2620700B1|1987-09-17|1990-06-01|Adir|PROCESS FOR THE SYNTHESIS OF ALPHA AMINO ACIDS N ALKYLS AND THEIR ESTERS. APPLICATION TO THE SYNTHESIS OF CARBOXYALKYL DIPEPTIDES|
    FR2620699B1|1987-09-17|1990-06-01|Adir|PROCESS FOR THE SYNTHESIS OF ALPHA AMINO N ALKYL ACIDS AND THEIR ESTERS. APPLICATION TO THE SYNTHESIS OF CARBOXYALKYL DIPEPTIDES|
    FR2620709B1|1987-09-17|1990-09-07|Adir|PROCESS FOR THE INDUSTRIAL SYNTHESIS OF PERINDOPRIL AND ITS MAIN INTERMEDIATE SYNTHESIS|
    FR2620703B1|1987-09-17|1991-10-04|Adir|PROCESS FOR THE INDUSTRIAL SYNTHESIS OF PERHYDROINDOLE CARBOXYLIC ACID - 2 . APPLICATION TO THE SYNTHESIS OF CARBOXYALKYL DIPEPTIDES|
    US4902695A|1989-02-13|1990-02-20|Eli Lilly And Company|Excitatory amino acid receptor antagonists|
    TW197945B|1990-11-27|1993-01-11|Hoechst Ag|
    LT3872B|1993-12-06|1996-04-25|Hoechst Ag|Novel peptides and pharmaceutical compositionscontaining them|
    AT212990T|1996-03-20|2002-02-15|Hoechst Ag|INHIBITORS OF BONE RESORPTION AND VITRONECTIN RECEPTOR ANTAGONISTS|
    FR2746394B1|1996-03-20|1998-05-29|Roussel Uclaf|NOVEL TRICYCLIC COMPOUNDS, THEIR PREPARATION PROCESS, AND INTERMEDIATES THEREOF, THEIR APPLICATION AS MEDICAMENTS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM|
    DE19653647A1|1996-12-20|1998-06-25|Hoechst Ag|Vitronectin receptor antagonists, their preparation and their use|
    DE19741873A1|1997-09-23|1999-03-25|Hoechst Marion Roussel De Gmbh|New 5-ring heterocycles, their preparation, their use and pharmaceutical preparations containing them|
    DE19751251A1|1997-11-19|1999-05-20|Hoechst Marion Roussel De Gmbh|Substituted imidazolidine derivatives, their manufacture, their use and pharmaceutical preparations containing them|
    DE19821483A1|1998-05-14|1999-11-18|Hoechst Marion Roussel De Gmbh|New imidazolidine derivatives useful as leukocyte adhesion and migration inhibitors and/or VLA-4 receptor antagonists for treating E.G. inflammatory and allergic disorders|
    FR2807431B1|2000-04-06|2002-07-19|Adir|NOVEL PROCESS FOR THE SYNTHESIS OF PERINDOPRIL AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS|
    FR2807430B1|2000-04-11|2002-05-17|Adir|NOVEL PROCESS FOR THE SYNTHESIS OF N - [ -1- CARBOXYBUTYL] --ALANINE ESTERS AND APPLICATION TO THE SYNTHESIS OF PERINDOPRIL|
    FR2811318B1|2000-07-06|2002-08-23|Adir|NOVEL GAMMA CRYSTALLINE FORM OF TERT-BUTYLAMINE SALT OF PERINDOPRIL, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME|
    FR2811320B1|2000-07-06|2002-08-23|Adir|NOVEL ALPHA CRYSTALLINE FORM OF TERT-BUTYLAMINE SALT OF PERINDOPRIL, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME|
    AU2007203451B2|2000-07-06|2010-09-02|Les Laboratoires Servier|Pharmaceutical composition containing a crystalline form of perindopril tert-butylamine salt|
    FR2827860B1|2001-07-24|2004-12-10|Servier Lab|NOVEL PROCESS FOR SYNTHESIS OF ACID DERIVATIVES-1 - [ -ALANYL] -OCTAHYDRO-1H-INDOLE-2-CARBOXYLINE AND APPLICATION TO THE SYNTHESIS OF PERINDOPRIL|
    SI1333026T1|2002-01-30|2007-10-31|Servier Lab|Process for the preparation of high purity perindopril and intermediates useful in the synthesis|
    FR2838648B1|2002-04-18|2004-05-21|Servier Lab|NEW PERINDOPRIL SALT AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING IT|
    GB2395195A|2002-11-18|2004-05-19|Cipla Ltd|Preparation of perindopril from carboxy-protected precursor, & perindopril monohydrates for use as angiotensin converting enzymeinhibitors|
    CN101333181A|2003-06-24|2008-12-31|瑟维尔实验室|Novel crystalline forms of perindopril erbumine|
    DE60303101T2|2003-06-30|2006-09-28|Les Laboratoires Servier|Process for the synthesis of perindopril and its pharmaceutically acceptable salts|
    SI1380590T1|2003-08-29|2006-12-31|Servier Lab|Method for synthesis of perindopril and its pharmaceutically acceptable salts|
    AT445588T|2003-09-01|2009-10-15|Servier Lab|A NEW METHOD FOR THE PRODUCTION OF ESTERS OF N--1-CARBOXYBUTYL) --ALANINE AND ITS USE IN THE SYNTHESIS OF PERINDOPRIL|
    SI21703A|2004-01-14|2005-08-31|Lek Farmacevtska Druzba Dd|Inclusion complexes of perindopril, procedure of their preparation, pharmaceutical compositions containing these complexes and their application in treatment of hypertensia|
    GB2413128A|2004-04-13|2005-10-19|Neopharma Ltd|Process for the preparation of perindopril|
    SI21800A|2004-05-14|2005-12-31|Krka, Tovarna Zdravil, D.D., Novo Mesto|New procedure of synthesis of perindopril|
    SI21881A|2004-10-15|2006-04-30|Diagen, Smartno Pri Ljubljani, D.O.O.|New crystal forms of perindopril erbumine hydrates, procedure of their preparation and pharmaceutical forms containing these compounds|
    SI1679072T1|2005-01-06|2009-02-28|Ipca Lab Ltd|Process for for synthesis of -1--alanyl-octahydro-1H-indole-2- carboxylic acid derivatives and use in the synthesis of perindopril|
    EP1815857A1|2006-02-02|2007-08-08|LEK Pharmaceuticals D.D.|A pharmaceutical composition comprising perindopril|
    FR2897866B1|2006-02-28|2008-04-18|Servier Lab|ALPHA CRYSTALLINE FORM OF PERINOPRIL ARGININE SALT, PROCESS FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME|
    SI22543A|2007-06-27|2008-12-31|Krka, Tovarna Zdravil, D.D., Novo Mesto|New salts of perindopril|
    GB0910692D0|2009-06-20|2009-08-05|Teva Pharma|Compound|
    PT105315B|2010-09-29|2013-01-16|Inst Superior Tecnico|A NEW CRYSTALIN HYDRATE FORM OF PERINDOPRIL ERBUMINE, METHODS FOR PREPARATION AND USE IN PHARMACEUTICAL PREPARATIONS|
    FR2985512B1|2012-01-05|2014-06-20|Servier Lab|PROCESS FOR THE PREPARATION OF L-ARGININE SALT OF PERINDOPRIL|
    FR2985511B1|2012-01-05|2014-01-03|Servier Lab|CRYSTALLINE DELTA FORM OF PERINOPRIL ARGININE SALT, PROCESS FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME|
    WO2016178591A2|2015-05-05|2016-11-10|Gene Predit, Sa|Genetic markers and treatment of male obesity|
    FR3050380B1|2016-04-20|2020-07-10|Les Laboratoires Servier|PHARMACEUTICAL COMPOSITION COMPRISING A BETA-BLOCKER, A CONVERSION ENZYME INHIBITOR AND AN ANTIHYPERTENSOR OR NSAID.|
    EP3842035A1|2019-12-23|2021-06-30|KRKA, d.d., Novo mesto|Composition for the preparation of perindopril arginine granules, a method for their preparation and pharmaceutical composition comprising the granules|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    FR8021095A|FR2491469B1|1980-10-02|1980-10-02|
    FR8106916A|FR2503155B2|1980-10-02|1981-04-07|LTRP981A| LT2504B|1980-10-02|1993-09-16|CHANGED AMINODIRUGSCIU, YOU RACEMATU OR OPTICAL ISOMER. OR THE RECEIPT OF THE PHARMACEUTICAL ACCEPTABLE SALT|
    LV931141A| LV5484A3|1980-10-02|1993-10-08|Attenuation to obtain substituted racemates or optical isomers of substituted aminodicarbonyls or their pharmaceutically acceptable islands|
    [返回顶部]